World Journal of
Pharmaceutical and Life Sciences

INVITRO EVALUATION OF ISONIAZID AND ITS DERIVATIVE (ISONIAZID GLUCURONATE SODIUM ANHYDROUS) FOR THE TREATMENT OF TUBERCULOSIS

Dr. Syed Ahmed Hussain* and Saniya Begum

ABSTRACT

Aim: To evaluate the cytotoxic and anti-angiogenic properties of Isoniazid glucuronate sodium anhydrous on
colorectal TB HT-29 cells and HUVEC endothelial cells. Objective: The study aimed to investigate the effects of
Isoniazid glucuronate sodium anhydrous on cell viability, tube formation, and the expression of proteins involved
in angiogenesis, such as NF-κB and VEGF-A, using MTT assay, Tubulogenesis assay, Indirect
Immunofluorescence assay, and Western Blot analysis. Research: The MTT assay demonstrated that treatment
with Isoniazid glucuronate sodium significantly decreased cell viability in HT-29 and HUVEC cells. The
Tubulogenesis assay revealed a reduction in the formation of tube-like structures, suggesting inhibition of
angiogenesis. Indirect Immunofluorescence and Western Blot analysis showed downregulation of NF-κB and
VEGF-A in HT-29 cells and VEGFR-2 in HUVEC cells. These results indicate that Isoniazid glucuronate sodium
affects key regulatory pathways involved in TB cell proliferation and angiogenesis. Conclusion: Isoniazid
glucuronate sodium anhydrous exhibited significant cytotoxic and anti-angiogenic activity by inhibiting cell
proliferation, reducing tube formation, and downregulating the expression of proteins critical for TB progression.
This suggests its potential as a novel therapeutic agent for TB treatment, warranting further in vivo and clinical
studies to confirm its efficacy.

[Full Text Article]   [Download Certificate]